Pfizer cuts 2026 revenue outlook amid COVID-19 & patent losses

The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion

ImmunityBio’s ANKTIVA wins EMA nod for early EU approval in hard-to-treat bladder cancer

Shelter Pharma launches D3 cure capsules

This launch is part of the company's strategy to expand its nutraceutical portfolio

Godavari Biorefineries ED Sangeeta Srivastava named BRSI Honorary Fellow

Dr Srivastava was selected by an expert jury in recognition of her sustained contributions to renewable chemicals, industrial biotechnology and bioprocess innovation

Pharma overhaul: EMA hails “Once-in-a-Generation” reform

The reform is set to modernise how medicines are developed, authorised, and made available across the EU

Sanofi secures two breakthrough nods in China for rare blood disorders

Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia

Sobi to acquire Arthrosi Therapeutics in $950 million deal, bolstering gout pipeline

The drug is currently being evaluated in two fully recruited global Phase 3 studies for progressive and tophaceous gout, with results expected in 2026.

Caplin Point Laboratories’ injectables facility completes INVIMA audit successfully

This is also an important milestone in our product strategy for our expansion into the larger Latin American market

Novartis appoints Vrinda Taneja as Director – People & Organisation, International India

Her journey includes leading HR for large and diverse teams across sales, marketing, corporate functions, and R&D

Lilly drug cuts risk of cancer progression, extends survival in advanced breast cancer trial

Updated results from the EMBER-3 study showed that the drug -- Inluriyo (imlunestrant) -- as a standalone treatment cut the risk of progression or death by 38%